Dr. Matthew W Johnson

EXCLUSIVE: Johns Hopkins Professor Says Psychedelic Medicine Could Get Messy, Calling For 'Right, Smart, Non-Restrictive, Yet Preventive' Regulations

Yetter Coleman’s Matt Zorn chatted with none other than multi-awarded and great psychedelics researcher Dr. Matthew Johnson at Benzinga’s recently held Psychedelics Capital Conference.

Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation

Mydecine Innovations Group (NEO: MYCO) (OTCPINK: MYCOF) has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, to study the application of psychedelics molecules and therapies in smoking cessation.